Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes - CNRS - Centre national de la recherche scientifique Access content directly
Journal Articles Annals of Hematology Year : 2022

Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes

No file

Dates and versions

hal-03876188 , version 1 (28-11-2022)

Identifiers

Cite

Meunier Mathieu, Chloé Friedrich, Nicolas Ducrot, Johanna Zannoni, Tondeur Sylvie, et al.. Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes. Annals of Hematology, 2022, 101 (12), pp.2633-2643. ⟨10.1007/s00277-022-04993-7⟩. ⟨hal-03876188⟩
7 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More